Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.

ABSTRACT:

Purpose

Trastuzumab improves overall survival for women with HER2-positive breast cancer but is associated with cardiotoxicity, especially when administered after anthracyclines. Use of non-anthracycline trastuzumab-based regimens is rising, particularly for patients with low-risk disease or with multiple cardiovascular risk factors. We performed a single-center retrospective cohort study to assess the cardiac safety of trastuzumab without anthracyclines outside of a clinical trial setting.

Methods

A retrospective chart review was conducted of patients with HER2-positive early-stage breast cancer receiving non-anthracycline trastuzumab-based therapy between January 2010 and June 2014. Cardiovascular risk factors, left ventricular ejection fraction (LVEF), and treatment inter

SUBMITTER: Yu AF 

PROVIDER: S-EPMC5647229 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature